Oxidant/antioxidant imbalance is an inherent feature of depression by unknown
Talarowska et al. BMC Psychiatry  (2015) 15:71 
DOI 10.1186/s12888-015-0454-5RESEARCH ARTICLE Open AccessOxidant/antioxidant imbalance is an inherent
feature of depression
Monika Talarowska1*, Janusz Szemraj2, Michael Berk3,4,5,6, Michael Maes6,7,8 and Piotr Gałecki1Abstract
Background: 50% to 60% of the people who have recovered from the first episode of depression experience a relapse.
The immune system of the people suffering from depression is in a permanent state of pathological pro-inflammatory
readiness. There are some reports that depressive episodes cause sensitization of immune-inflammatory pathways and
that staing of depression (e.g. number of depressive episodes) is correlated with immune-inflammatory markers.
The main objective of the study was to delineate whether recurrent major depression (rDD) is characterized by
alterations in selected immune-inflammatory biomarkers as compared with first episode of depression (ED-I), i.e.
expression of mRNA and enzymatic activity of manganese superoxide dismutase (MnSOD, SOD-2), myeloperoxidase
(MPO), inducible nitric oxide synthase (iNOS, NOS-2), and cyclooxygenase-2 (COX-2).
Methods: The study was carried out in a group of 131 patients: ED-I group – 42 patients, rDD group – 89 patients.
Depression severity was assessed with the 17-item Hamilton Depression Rating Scale (HDRS). The number of
depression episodes and the disease duration periods were recorded in each patient. For the patients, HDRS was
administered at admission during the symptomatic phase, which would generally be either before or shortly after
modification of the previous antidepressant drug regimen. Reassessment of the mental condition was conducted
after 8 weeks of the pharmacological treatment also with the use of the HDRS scale.
Results: No significant statistical differences were found between the analysed groups as regards the intensity of
depressive disorders. No differences in the expression of MnSOD, MPO, COX-2 and i-NOS genes on the level of
both mRNA and protein were observed between both groups. No significant interrelation was noticed between
the number of depression episodes experienced and the expression of selected genes on the mRNA level and
protein level.
Conclusions: There is no significant difference in MnSOD, MPO, COX-2 and i-NOS between patients with recurrent
depressive disorders and those in a first episode of depression. These findings suggest that these enzymes are trait
markers of depression and are not related to staging of depression.
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Annual prevalence of depression in the adult population
oscillates between 6% and 12%, and – according to dif-
ferent sources – varies from 5% to even 30% among
people over the age of 65 [1]. Depression often accom-
panies other diseases, which means its symptoms are ob-
served in approximately 10% of all adults within one
year (this corresponds to 100 million cases).* Correspondence: talarowskamonika@wp.pl
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unless otherwise stated.Episodes of lower mood last relatively long – from 6
to 9 months. The disease may also take a chronic form,
resistant to treatment. Age, at which the first episode
takes place, as well as duration, frequency and intensity
of episodes are characterised by individual variability [2].
50% to 60% of the people who have recovered from
the first episode of depression experience a relapse. In
the majority of hospitalised patients another depressive
episode appears within the next two years of discharging
from the hospital. It is estimated that some 20% of the
affected with diagnosed recurrent depressive disorders
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Every successive episode is associated with a less positive
prognosis and poorer response to pharmacological treat-
ment [4].
The first hypothesis that macrophages may play a role
in depression was published in 1991 by Ronald Smith
[5], whereas the first original reports on activation of
immune-inflammatory pathways in depression were
reported as of 1990 by Maes et al. Today, it is agreed
that the immune system of the people suffering from
depression is in a permanent state of pathological
pro-inflammatory readiness [6]. The symptoms of an
ongoing inflammatory process, like fatigue, sleep dis-
orders, anxiety, low mood, loss of appetite or anhedonia,
correspond to the symptoms of depressive disorders [7,8].
On the other hand, not only proinflammatory cytokines,
e.g. tumor necrosis factor-alpha – (TNF-α), the interleu-
kins (IL) and interferon-gamma (IFN-gamma), but also
anti-inflammatory cytokines are released by CNS and
peripheral-derived immune cells and play a powerful
role in depression [9]. There are data that depressive
episodes are accompanied by an increased sensitization
of immune-inflammatory pathways and that the number
of depressive episodes is correlated with immune-
inflammatory markers such as TNF-α and neopterin [10].
The main objective of the study was to examine
whether recurrent major depression (rDD) is accompan-
ied by more profound inflammatory disturbances than
the first episode of depression (ED-I), i.e. expression of
mRNA and protein levels of four inflammatory enzymes,
i.e. manganese superoxide dismutase (MnSOD, SOD-2),
myeloperoxidase (MPO), inducible nitric oxide synthase
(iNOS, NOS-2), and cyclooxygenase-2 (COX-2). Not
only do the aforementioned compounds take part in an
inflammatory reaction, but they are also active in the
production of free radicals, and damage proteins, fatty
acids and cellular DNA [11,12]. In our previous studies,
we demonstrated that the selected variables (COX-2,
iNOS, MnSOD, MPO) can have a significant impact on
cognitive functioning in patients with rDD. Therefore,
we have made an attempt to assess the level of selected
indicators at different stages of the disease (rDD).
Subjects
The study was carried out in a group of 131 patients:
ED-I group – 42 patients, rDD group – 89 patients. All
patients were hospitalised at Department of Adult
Psychiatry Medical University of Lodz (Poland). The se-
lection of individuals for the study group was performed
randomly without replacement sampling.
The patients were selected for the study based on the
inclusion criteria for ED and rDD outlined in ICD-10
(F32.0-7.32.2, F33.0-F33.8) [13]. The presence of axis I
and II disorders, other than depressive episode, and thediagnosis of somatic diseases and injuries of the central
nervous system (CNS), were regarded as exclusion cri-
teria. Other exclusion criteria were: inflammatory or
autoimmune disorders and unwilling to give informed
consent. For all the subjects, a case history was obtained
prior to participation using the standardised Composite
International Diagnostic Interview (CIDI) [14].
All the subjects were free from medical illnesses, in-
cluding infections and inflammatory or allergic reac-
tions. None of the control subjects or depressed patients
was treated with drugs known to influence lipid metab-
olism, immune response or endocrine function. None of
the participants were drinkers or heavy smokers, and
none had ever taken psychotropic drugs.Methods
Severity of depression
Depression severity was assessed with the 17-item
Hamilton Depression Rating Scale (HDRS). A descrip-
tion of HDRS has been presented elsewhere [15,16].
All the subjects were examined during the course of
their hospitalisation. The study group included subjects,
hospitalised for the first time for depressive episode and
depression treatment-naïve, as well as those, treated for
many years before and with multiple hospitalisation epi-
sodes in history, the latter admitted for various degrees
of health deterioration. The number of depression epi-
sodes and the disease duration periods were recorded in
each patient.
For the patients, HDRS was administered at admission
during the symptomatic phase, which would generally be
either before or shortly after modification of the previ-
ous antidepressant drug regimen. Reassessment of the
mental condition was conducted after 8 weeks of the
pharmacological treatment also with the use of the
HDRS scale. Examination of patients was conducted by
the same person in each case.
Whole blood samples from the patients were collected
in 5 ml EDTA-containing tubes than centrifuge at
1000xg for 10 min at 4 degrees C and used for isolation
peripherial blood lymphocytes. Lymphocytes and serum
stored at – 70°C until analysedmRNA and serum protein expression
COX-2 mRNA and serum protein expression
Analyses were performed according to methods previ-
ously described: mRNA expression in the peripheral
blood lymphocytes was quantified by real-time PCR
using ABI Prism 7000 Sequence Detection System
(Applied Biosystems, Foster City, Calif., USA) according
to the manufacturer’s protocol [17], serum protein level
by ELISA method (COX-2 ELISA Kit, Calbiochem, Merck
KGaA, Darmstadt, Germany).
Table 1 The comparison of the study groups in terms of
sex and education
Sex ED-I (N = 42) rDD (N = 89) Total
N (%) N (%) N (%)
Female 19 (45.24) 57 (64.04) 76 (58.01)
Male 23 (54.76) 32 (35.96) 55 (41.98)
Education ED-I (N = 42) rDD (N = 89) Total
N (%) N (%) N (%)
Primary 1 (2.38) 9 (10.11) 10 (7.63)
Vocational 11 (26.19) 18 (20.22) 29 (22.14)
Secondary 20 (47.62) 46 (51.69) 66 (50.38)
High 10 (23.81) 16 (17.98) 26 (19.85)
ED-I – first episode of depression, rDD – recurrent depressive disorders, n – number
of samples, % – percentage.
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Nitric oxide was estimated in plasma with the use of
Nitric Oxide Non-Enzymatic Assay (cat. No. 12111)
Oxis International, Inc. Bioxytech.
Concentration of NO was measured in terms of its
products nitrite (NO2-) and nitrate (NO3-). The test is
based on the reduction of nitrate to nitrite using the
granulated cadmium and conversion, using Greiss reagent,
of nitrite into a purple compound – chromophore, which
is measured colometrically at 540 nm. NO products are
expressed as μM/L of plasma. The human iNOS and
GADPH expression the peripheral blood lymphocytes
was quantified by real-time PCR using ABI Prism 7000
Sequence Detection System (Applied Biosystems, Foster
City, Calif., USA) according to the manufacturer’s
protocol [18].
MnSOD mRNA and serum protein expression
The test protein levels were measured in blood serum
levels for each patient. These tests were preceded by a
determination of serum total protein. Two measurement
techniques were employed [19]. For the quantitative
detection of serum SOD2 protein levels, a commercial
kit, NWLSSTM MnSOD ELISA, was used (Northwest
Life Science Specialties LLC, Vancouver, Wash., USA).
The human MnSOD and GADPH expression the per-
ipheral blood lymphocytes was quantified by real-time
PCR using ABI Prism 7000 Sequence Detection System
(Applied Biosystems, Foster City, Calif., USA) accord-
ing to the manufacturer’s protocol [19].
MPO mRNA and serum protein expression
For the quantitative detection of circulating serum MPO
protein level, the commercial Human MPO Immuno-
assay from R&D Systems, Inc. (Minneapolis, MN, USA),
was used. Total RNA (1 μg) was extracted from the the
peripheral blood lymphocytes using Trizol reagent (Life
Technologies Inc.), and was processed directly to cDNA
synthesis using the TaqMan Reverse Transcription Reagents
kit (Applied Biosystem) according to the manufacturer’s
protocol [20].
Statistical analysis
A statistical analysis of the collected material included
calculation of both descriptive and inferential statistics.
A two-tailed critical region was employed in the statis-
tical hypothesis testing.
Qualitative characteristics of the experimental and
control groups were expressed as frequencies shown as
percentages. To characterise the average values for
quantitative features, the arithmetical mean (M) and
median (Me) were calculated. The measures of statis-
tical dispersion included the range of values betweenthe minimum and the maximum, and the standard de-
viation (SD).
Distributions were analysed using the Shapiro-Wilk
test. To compare nonparametric variables in the test
groups, the following tests were used: the Pearson χ2 for
qualitative variables, the Wilcoxon signed-rank test for
two related groups for quantitative variables, and the
Mann–Whitney U test for two independent groups to
determine the coincidence of distributions. To evaluate
the relations between the analysed variables, Spearman's
R rank order correlation coefficients were estimated.
For all analyses, statistical significance was defined as
p <0.05 [21]. All data analyses were performed using
STATISTICA PL, version 10.
Ethics
Before deciding to participate in the study, the subjects
were informed of the purpose of the study, assured for
voluntary participation, and guaranteed with personal
data confidentiality. Written informed consent was ob-
tained according to the study protocol that was ap-
proved by the Bioethical Committee of the Medical
University of Lodz (No. RNN/728/12/KB).
Results
Average age of all the examined patients (N = 131) was:
M = 48.53 years, SD = 11.05; minimum age – 20 years,
maximum – 67 years. In the ED-I group, average age
was: M = 44.72, SD = 13.03, and in the rDD group: M =
49.89, SD = 9.68. The characteristics of the examined
group in Table 1.
No significant statistical differences were found be-
tween the examined groups in terms of sex (χ2 = 4.14,
p = 0.41) and education (χ2 = 3.27, p = 0.35), only in
terms of age (Z = 2.21, p = 0.03).
Significant statistical differences were observed be-
tween severity of depression as measured with the
HDRS scale in the ED-I and rDD groups on the day of
Table 3 Average standard deviation, minimum and
maximum values of expression of selected genes on the
mRNA level and protein level in the examined group
(N = 131)
Variable rDD
M (SD) Min. Max.
MnSOD 0.54 0.21 0.83
mRNA (2-ΔΔct) (0.17)
MnSOD 175.37 67 294
protein (pg/ml) (64.74)
MPO 0.31 0.23 0.43
mRNA (2-ΔΔct) (0.04)
MPO 308.95 219 421
protein (ng/ml) (39.94)
COX-2 0.24 0.13 0.33
mRNA (2-ΔΔct) (0.04)
COX-2 114.66 47 212
protein (ng/ml) (24.67)
iNOS 0.11 0.05 0.18
mRNA (2-ΔΔct) (0.02)
iNOS 20.71 4.91 43.61
protein (U/ml) (8.19)
MnSOD – manganese superoxide dismutase, MPO – myeloperoxidase, COX-2 –
cyclooxygenase-2, iNOS – cytokine-inducible nitric oxide synthase, M – mean,
SD – standard deviation.
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response to the applied pharmacological treatment
(respectively Z = 5.64, p < 0.001 and Z = 8.18, p < 0.001).
This result indicates an improvement in the effect of the
incorporated treatment in both the examined groups.
No significant statistical differences were found between
the analysed groups as regards the severity of depressive
disorders (Table 2). Neither were such differences ob-
served on the day of admission of the patients to the ex-
periment as well as after receiving a response to the
implemented pharmacological treatment. In both groups,
average level of the symptoms of depressive disorders on
the first day of the experiment corresponded to severe
level of depressive disorders acc. to the HDRS scale and
remission of depressive disorders according the HDRS
scale after 8 weeks of the pharmacological therapy.
Table 3 presents average values, standard deviation,
minimum and maximum values of expression on the
mRNA level and the protein level for the analysed in-
flammation enzymes: MnSOD, MPO, COX-2 and iNOS
in the examined group (N = 131).
Table 4 presents a comparison of expression of the
analysed genes on the mRNA level and protein level in
the affected from the ED-I and rDD group.
In case of all the variables included in the analysis, no
significant statistical differences were found between the
ED-I and rDD group. No differences in the expression of
MnSOD, MPO, COX-2 and i-NOS genes on the level of
both mRNA and protein were observed between the pa-
tients with the first episode of depression and diagnosed
with rDD.
An average number of depression episodes totalled
6.48 among the patients suffering from rDD (Table 2).
No significant interrelation was noticed between the
number of depression episodes experienced and the ex-
pression of selected genes on the mRNA level and pro-
tein level.
In the examined group, there was no significant rela-
tionship between the severity of depressive disorders
measured before and after pharmacotherapy and theTable 2 The severity of depressive disorders among ED-I
group and rDD group
Variable ED-I (N = 42) rDD (N = 89) Mann–Whitney
U test
M (SD) M (SD) Z p
HDRS-I 22.73 (6.51) 24.06 (6.59) −0.622 0.534
HDRS-II 5.62 (3.76) 6.86 (4.01) −1.53 0.126
Number of depression
episodes
- 6.48 (5.81) - -
ED-I – first episode of depression, rDD-recurrent depressive disorders, HDRS-I – Hamilton
Depression Rating Scale at the onset of therapy, HDRS-II – Hamilton Depression
Rating Scale after pharmacological treatment, M – mean, SD – standard deviation.expression on the mRNA level and protein level for the
analysed genes.
Discussion
The working hypothesis presented in the introduction
was not confirmed. The obtained results indicate no dif-
ferences in the expression of inflammation enzymes
(MnSOD, MPO, COX-2 and iNOS) between patients
with the first episode of depression and rDD. However,
in our previous experiments we showed that the expres-
sion of mRNA and enzyme activity of MnSOD was sig-
nificantly lower in rDD patients than in controls [19], a
phenomenon which could point toward an adaptive
MnSOD response to inflammation and increased oxida-
tive stress. Previously, we have shown that myeloperoxi-
dase [20], cyclooxygenase-2 [17] and inducible nitric
oxide synthase [18] mRNA expression and protein levels
were significantly higher in patients with recurrent de-
pressive disorders than in healthy controls. Therefore,
the results may indicate actively progressing immune-
inflammatory and oxidative stress processes in patients
with depression, although the magnitude of biomarkers
measured here does not depend of the phase of the dis-
ease Table 5.
There are no studies which have compared the bio-
markers we have used between both depression groups
Table 4 Comparison of expression of the analysed genes
on the mRNA level and protein level in the affected from
the ED-I and rDD group
Variable ED-I rDD Mann–Whitney U test
M (SD) M (SD) Z p
MnSOD 0.529 0.548 0.266 0.791
mRNA (2-ΔΔct) (0.189) (0.158)
MnSOD 172.26 176.83 0.283 0.776
protein (pg/ml) (72.78) (60.97)
MPO 0.319 0.314 −0.531 0.596
mRNA (2-ΔΔct) (0.037) (0.041)
MPO 311.16 307.91 −0.271 0.786
protein (ng/ml) (38.08) (40.96)
COX-2 0.242 0.235 −0.806 0.421
mRNA (2-ΔΔct) (0.039) (0.038)
COX-2 116.47 113.79 −0.483 0.628
protein (ng/ml) (24.84) (24.71)
iNOS 0.103 0.101 −0.086 0.931
mRNA (2-ΔΔct) (0.023) (0.022)
iNOS 21.01 20.56 0.044 0.964
protein (U/ml) (8.66) (8.02)
ED-I – first episode of depression, rDD – recurrent depressive disorder, MnSOD –
manganese superoxide dismutase, MPO – myeloperoxidase, COX-2 – cyclooxygenase-2,
iNOS – cytokine-inducible nitric oxide synthase, M – mean, SD – standard deviation.
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reports of other researchers. However, referring to the
work by Sarapas et al. [22] we shall use two expressions
in this place – the so-called state effects and trait-like re-
lationship. According to the first hypothesis, an increase
of inflammation factors observed during an episode of
depression is only a transient condition, which dis-
appears in the period of disease remission. Based on the
second hypothesis, increased pro-inflammatory andTable 5 The significance of inflammation enzymes in the aeti
MnSOD First line of defence against damage caused as a result of excessive p
Experiments of recent years indicate that MnSOD protects cells of the
MnSOD also protects cells of the CA3 region of the hippocampus aga
MPO Protein of an immuno-inflammatory response and prooxidative enz
processes in the patients with depression [35]. MPO is a heme enzy
cells, which indicates its crucial role in the regulation of inflammato
leads to the production of hypochlorous acid and other toxic oxidi
may be considered a biomarker of inflammation in the course of rD
COX-2 COX-2 inhibition restricts the formation of reactive oxygen species
pituitary gland – adrenal glands axis, and an increase of the level o
iNOS Plays a decisive role not only in numerous biological processes, but
be significant in the aetiology of anxiety and depressive disorders (
and synaptic plasticity) [40,41]. Nitrous oxide – being one of free ra
neuroprotective role in physiological conditions. Nevertheless, if pro
the action of nitrous oxide becomes harmful; then, it undergoes ox
as reactive nitrogen species (RNS), which cause cell damage. Both N
neurodegenerative diseases [42].
MnSOD – manganese superoxide dismutase, MPO – myeloperoxidase, COX-2 – cyclooxanti-inflammatory activation is a permanent feature ac-
companying patients who suffer from depression. The
present results show that alterations in the enzymes
measured here are trait markers, whereas previous re-
search showed that increases in TNF-α and neopterin
should be regarded as staging markers [10]. In any case,
it seems justified to conclude that some activated
immune-inflammatory and oxidative stress pathways
may be considered as endophenotypic trait biomarkers
of depression, whereas other assays are biomarkers of
staging of depression.
In the examined group, there were no significant rela-
tionships between the severity of depressive disorders mea-
sured before and after pharmacological treatment and the
expression of mRNA and protein levels of the enzymes.
Moreover, the relationship between rDD level and MPO
concentration in blood serum was not confirmed by
Vaccarino et al. [23]. Meanwhile, in the experiments con-
ducted by Sarandol et al. [24], a raised level of SOD-2 in
the group of patients with the so-called major depressive
disorder positively correlated with the intensity of symp-
toms of depressive disorders. Similar conclusions were
drawn from the work by Su et al. [25], who evaluated the
concentration of inflammatory markers such as IL-6 and
C-reactive protein. Additionally, it was demonstrated that
increased concentration of IL-2 correlated with the risk of
an attempted suicide [26].
Antidepressant treatments may reduce oxidative stress
[27-29]. However, Gałecki et al. [30] did not find a
change in the concentration of antioxidative enzymes
(catalase and zinc superoxide dismutase) after 3 months
fluoxetine pharmacotherapy in patients with rDD (n = 50).
The concentration of the said compounds – both before
onset of the treatment and after observing a symptomatic
improvement in the examined group of patients with
rDD – was higher than in healthy individuals. Inology of depression
roduction of the superoxide anion radical by the mitochondrion [9].
CA1 region of the hippocampus against apoptosis [33]. Additionally,
inst generation of free radicals during excessive glutamatergic activity [34].
yme, which may be a marker of inflammation as well as prooxidative
me whose expression is observed in both cells of the brain and immune
ry processes and the formation of oxidative stress [36]. MPO activation
sing agents [37]. According to Vaccarino et al. [23], a raised level of MPO
D.
[38]. COX-2 also affects an increase of activity in the hypothalamus –
f pro-inflammatory cytokines [39].
also in the regulation of cognitive and emotional functions, which may
most of all through participation in neuromodulation, neurotransmission
dicals – takes part in the regulation of oxidative stress [12]. NO plays a
duced in excess, or if cells are under the influence of oxidative stress,
idation and reduction processes producing toxic compounds referred to
O and RNS play a role in the pathogenesis and development of many
ygenase-2, iNOS – cytokine-inducible nitric oxide synthase.
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reduction of catalase and zinc superoxide dismutase in
serum) was possible after combining fluoxetine-based
pharmacotherapy with acetylsalicylic acid (non-steroid
anti-inflammatory drug). Similar results were recorded
by Whittle et al. [32] in an experiment based on an ani-
mal model.
In summary, it is possible to confirm the necessity for
further research studies as regards the presented issues
and mutual interrelations between inflammatory pro-
cesses and emotional and cognitive signs of depression.
Conclusions
There is no significant difference in MnSOD, MPO,
COX-2 and i-NOS between patients with recurrent de-
pressive disorders and those in a first episode of depres-
sion. These findings suggest that these enzymes are trait
markers of depression and are not related to staging of
depression.
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